<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380119</url>
  </required_header>
  <id_info>
    <org_study_id>imm02</org_study_id>
    <secondary_id>LisichnskRTD</secondary_id>
    <nct_id>NCT01380119</nct_id>
  </id_info>
  <brief_title>Tuberculosis (TB) Immunotherapy Phase 2 Study</brief_title>
  <acronym>imm02</acronym>
  <official_title>Phase 2 Study of Orally Formulated Heat-killed Mycobacterium Vaccae Study in TB Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisichansk Regional Tuberculosis Dispensary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical University, Ukraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immunitor USA Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lisichansk Regional Tuberculosis Dispensary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, randomized, placebo-controlled trial, aimed to seek the therapeutic
      benefit of V7 in combination with standard of care anti-Tuberculosis (TB) therapy (ATT) among
      Mycobacterium tuberculosis-infected sputum smear positive subjects. The results will be
      compared to placebo combined with standard ATT therapy. The trial will consist of one stage
      with sputum evaluation at months 1 and 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sputum conversion</measure>
    <time_frame>2 months</time_frame>
    <description>To compare the efficacy of combination of V7 with anti-TB treatment versus anti-TB treatment+placebo in adults with pulmonary tuberculosis including:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>1 and 2 months</time_frame>
    <description>Liver functions tests (AST and ALT, and bilirubin) as main biochemical tests
To confirm quality of life improvement by specially designed questionnaire TB score
The beneficial effect on TB-associated wasting by measuring body weight.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>V7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral pill containing heat-killed Mycobacterium vaccae</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identically appearing placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V7</intervention_name>
    <description>experimental arm</description>
    <arm_group_label>V7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo pill</description>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are at least 18 years old and are willing and capable of providing
             informed consent. Both men and non-pregnant women will be included.

          -  TB infection documented prior to Study Entry by sputum smear positive for acid-fast
             bacilli (AFB) test.

          -  TB score status at baseline.

          -  Agreement to participate in the study and to give a sample of blood for lab testing.

          -  Readily available home or other address where patient can be found.

        Exclusion Criteria:

          -  Subjects who might have already taken V5 in prior trial and have no baseline data.
             Pregnant or breast-feeding women are excluded.

          -  Subjects who have taken study unrelated drugs or immunomodulatory therapies during
             study or prior to Entry.

          -  Medical conditions such as active alcohol or substance abuse, or psychological issues
             that in the opinion of the local investigator would interfere with adherence to the
             requirements of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldar Bourinbaiar, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Immunitor USA Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lisichansk TB Dispensary</name>
      <address>
        <city>Lisichansk</city>
        <state>Luhansk</state>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <reference>
    <citation>Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Frolov VM, Tarakanovskaya MG, Batdelger D, Jirathitikal V, Bourinbaiar AS. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy. 2011 Feb;3(2):181-91. doi: 10.2217/imt.10.96. Epub 2010 Dec 24.</citation>
    <PMID>21182457</PMID>
  </reference>
  <reference>
    <citation>Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Vihrova LA, Pylypchuk VS, Frolov VM, Kutsyna GA. Enhancement of efficacy of tuberculosis drugs with Immunoxel (Dzherelo) in HIV-infected patients with active pulmonary tuberculosis. Immunotherapy. 2009 Jul;1(4):549-56. doi: 10.2217/imt.09.25.</citation>
    <PMID>20635986</PMID>
  </reference>
  <reference>
    <citation>Butov DA, Pashkov YN, Stepanenko AL, Choporova AI, Butova TS, Batdelger D, Jirathitikal V, Bourinbaiar AS, Zaitzeva SI. Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J Immune Based Ther Vaccines. 2011 Jan 18;9:3. doi: 10.1186/1476-8518-9-3.</citation>
    <PMID>21244690</PMID>
  </reference>
  <results_reference>
    <citation>Efremenko YV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Butova TS, Stepanenko AL, Kutsyna GA, Jirathitikal V, Bourinbaiar AS. Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum Vaccin Immunother. 2013 Sep;9(9):1852-6. doi: 10.4161/hv.25280. Epub 2013 Jun 19.</citation>
    <PMID>23782489</PMID>
  </results_reference>
  <results_reference>
    <citation>Butov DA, Efremenko YV, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Butova TS, Stepanenko AL, Kutsyna GA, Jirathitikal V, Bourinbaiar AS. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7). Immunotherapy. 2013 Oct;5(10):1047-54. doi: 10.2217/imt.13.110.</citation>
    <PMID>24088075</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>October 25, 2013</last_update_submitted>
  <last_update_submitted_qc>October 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sputum conversion</keyword>
  <keyword>liver biochemistry</keyword>
  <keyword>weight loss</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 18, 2014</submitted>
    <returned>April 21, 2014</returned>
    <submitted>September 8, 2014</submitted>
    <returned>September 11, 2014</returned>
    <submitted>September 11, 2016</submitted>
    <returned>October 27, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

